Major depressive disorder.

Standard

Major depressive disorder. / Otte, Christian; Gold, Stefan; Penninx, Brenda W; Pariante, Carmine M; Etkin, Amit; Fava, Maurizio; Mohr, David C; Schatzberg, Alan F.

In: NAT REV DIS PRIMERS, Vol. 2, 15.09.2016, p. 16065.

Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

Harvard

Otte, C, Gold, S, Penninx, BW, Pariante, CM, Etkin, A, Fava, M, Mohr, DC & Schatzberg, AF 2016, 'Major depressive disorder.', NAT REV DIS PRIMERS, vol. 2, pp. 16065. https://doi.org/10.1038/nrdp.2016.65

APA

Otte, C., Gold, S., Penninx, B. W., Pariante, C. M., Etkin, A., Fava, M., Mohr, D. C., & Schatzberg, A. F. (2016). Major depressive disorder. NAT REV DIS PRIMERS, 2, 16065. https://doi.org/10.1038/nrdp.2016.65

Vancouver

Otte C, Gold S, Penninx BW, Pariante CM, Etkin A, Fava M et al. Major depressive disorder. NAT REV DIS PRIMERS. 2016 Sep 15;2:16065. https://doi.org/10.1038/nrdp.2016.65

Bibtex

@article{48cdba0c8ed346b88bc3e28bf6854fde,
title = "Major depressive disorder.",
abstract = "Major depressive disorder (MDD) is a debilitating disease that is characterized by depressed mood, diminished interests, impaired cognitive function and vegetative symptoms, such as disturbed sleep or appetite. MDD occurs about twice as often in women than it does in men and affects one in six adults in their lifetime. The aetiology of MDD is multifactorial and its heritability is estimated to be approximately 35%. In addition, environmental factors, such as sexual, physical or emotional abuse during childhood, are strongly associated with the risk of developing MDD. No established mechanism can explain all aspects of the disease. However, MDD is associated with alterations in regional brain volumes, particularly the hippocampus, and with functional changes in brain circuits, such as the cognitive control network and the affective-salience network. Furthermore, disturbances in the main neurobiological stress-responsive systems, including the hypothalamic-pituitary-adrenal axis and the immune system, occur in MDD. Management primarily comprises psychotherapy and pharmacological treatment. For treatment-resistant patients who have not responded to several augmentation or combination treatment attempts, electroconvulsive therapy is the treatment with the best empirical evidence. In this Primer, we provide an overview of the current evidence of MDD, including its epidemiology, aetiology, pathophysiology, diagnosis and treatment.",
keywords = "Journal Article",
author = "Christian Otte and Stefan Gold and Penninx, {Brenda W} and Pariante, {Carmine M} and Amit Etkin and Maurizio Fava and Mohr, {David C} and Schatzberg, {Alan F}",
year = "2016",
month = sep,
day = "15",
doi = "10.1038/nrdp.2016.65",
language = "English",
volume = "2",
pages = "16065",
journal = "NAT REV DIS PRIMERS",
issn = "2056-676X",
publisher = "NATURE PUBLISHING GROUP",

}

RIS

TY - JOUR

T1 - Major depressive disorder.

AU - Otte, Christian

AU - Gold, Stefan

AU - Penninx, Brenda W

AU - Pariante, Carmine M

AU - Etkin, Amit

AU - Fava, Maurizio

AU - Mohr, David C

AU - Schatzberg, Alan F

PY - 2016/9/15

Y1 - 2016/9/15

N2 - Major depressive disorder (MDD) is a debilitating disease that is characterized by depressed mood, diminished interests, impaired cognitive function and vegetative symptoms, such as disturbed sleep or appetite. MDD occurs about twice as often in women than it does in men and affects one in six adults in their lifetime. The aetiology of MDD is multifactorial and its heritability is estimated to be approximately 35%. In addition, environmental factors, such as sexual, physical or emotional abuse during childhood, are strongly associated with the risk of developing MDD. No established mechanism can explain all aspects of the disease. However, MDD is associated with alterations in regional brain volumes, particularly the hippocampus, and with functional changes in brain circuits, such as the cognitive control network and the affective-salience network. Furthermore, disturbances in the main neurobiological stress-responsive systems, including the hypothalamic-pituitary-adrenal axis and the immune system, occur in MDD. Management primarily comprises psychotherapy and pharmacological treatment. For treatment-resistant patients who have not responded to several augmentation or combination treatment attempts, electroconvulsive therapy is the treatment with the best empirical evidence. In this Primer, we provide an overview of the current evidence of MDD, including its epidemiology, aetiology, pathophysiology, diagnosis and treatment.

AB - Major depressive disorder (MDD) is a debilitating disease that is characterized by depressed mood, diminished interests, impaired cognitive function and vegetative symptoms, such as disturbed sleep or appetite. MDD occurs about twice as often in women than it does in men and affects one in six adults in their lifetime. The aetiology of MDD is multifactorial and its heritability is estimated to be approximately 35%. In addition, environmental factors, such as sexual, physical or emotional abuse during childhood, are strongly associated with the risk of developing MDD. No established mechanism can explain all aspects of the disease. However, MDD is associated with alterations in regional brain volumes, particularly the hippocampus, and with functional changes in brain circuits, such as the cognitive control network and the affective-salience network. Furthermore, disturbances in the main neurobiological stress-responsive systems, including the hypothalamic-pituitary-adrenal axis and the immune system, occur in MDD. Management primarily comprises psychotherapy and pharmacological treatment. For treatment-resistant patients who have not responded to several augmentation or combination treatment attempts, electroconvulsive therapy is the treatment with the best empirical evidence. In this Primer, we provide an overview of the current evidence of MDD, including its epidemiology, aetiology, pathophysiology, diagnosis and treatment.

KW - Journal Article

U2 - 10.1038/nrdp.2016.65

DO - 10.1038/nrdp.2016.65

M3 - SCORING: Journal article

C2 - 27629598

VL - 2

SP - 16065

JO - NAT REV DIS PRIMERS

JF - NAT REV DIS PRIMERS

SN - 2056-676X

ER -